Long after reproductive life concludes, human ovaries undergo continuous molecular remodeling characterized by rising inflammation, extracellular matrix alterations, and shifts in cellular signaling, according to a study published on the preprint server bioRxiv and detailed in Aging Cell.
For generations, clinical consensus regarded the postmenopausal ovary as an inert, fibrous structure devoid of active biological function once ovulation ceased. However, investigators analyzing healthy ovarian tissue from 28 postmenopausal women aged 50 to 75 have challenged this assumption. Using advanced mass spectrometry techniques, researchers mapped thousands of proteins to establish that these organs maintain dynamic metabolic and immune activity long after the cessation of menses, opening new avenues of investigation into chronic disease and oncology.
Decoding Ovarian Proteomic Shifts Across Decades
To evaluate how ovarian tissue evolves over time, researchers stratified the 28 tissue samples into three distinct cohorts: women aged 50 to 59, 60 to 69, and 70 years and older. By employing data-independent acquisition mass spectrometry with parallel accumulation-serial fragmentation (diaPASEF), the investigative team quantified 5,812 protein groups to isolate age-associated molecular shifts.
A groundbreaking study shows that ovaries don’t shut down after menopause, but turn into organs with a new function.For decades, the medical community viewed postmenopausal ovaries as biologically inert, having completed their reproductive lifespan. However, a new study… pic.twitter.com/J93UyDFQd9
The comparative proteomic analysis revealed modest differences between adjacent age brackets, but stark contrasts when comparing the youngest postmenopausal cohort to women aged 70 and older. Specifically, women aged 60 to 69 demonstrated significant variations in 40 protein groups compared to the 50–59 age bracket, with 34 proteins increasing in abundance. These elevations clustered primarily around immune responses, inflammation, and tissue remodeling.
In the oldest cohort—women aged 70 and above—117 protein groups showed statistically significant changes relative to the baseline group. Among these, 84 proteins declined, notably structural components responsible for maintaining cellular architecture and keratinization. Concurrently, 33 proteins increased, highlighting persistent metabolic shifts and heightened innate immune pathway activity. Linear regression modeling further isolated two individual proteins with pronounced trajectory changes: fatty acid-binding protein 5 (FABP5), which decreased by approximately 29% per decade, and heparan-sulfate 6-O-sulfotransferase 2 (HS6ST2), which increased by roughly 58% per decade after adjusting for body mass index and ethnicity.
Establishing the BuckPOMS Molecular Signature
To operationalize these findings, the research team developed a 26-protein signature of postmenopausal ovarian aging termed the Buck Postmenopausal Ovary Molecular Signature (BuckPOMS). This composite score rises progressively across advancing age groups, reflecting systemic molecular processes observed in other aging human tissues.
Despite its correlation with chronological aging, the BuckPOMS framework remains an exploratory tool. Because the signature was both developed and assessed within the same initial cohort of 28 participants, its predictive capacity has not yet undergone independent clinical validation. Furthermore, the underlying dataset did not capture specific clinical variables such as age at natural menopause, exact duration since the final menstrual period, or historical use of menopausal hormone therapy.
ScienceAlert noted that these protein trajectories mirror parallel findings observed earlier in murine models by investigators studying age-related shifts in ovarian tissue. While animal models demonstrate predictable protein transitions, translating these pathways to human clinical management requires rigorous multi-center validation.
Implications for Ovarian Cancer Risk and Cellular Senescence
The discovery of persistent molecular activity in aging ovaries sheds new light on epidemiological data showing that ovarian cancer risk rises steeply with advancing age. When investigators cross-referenced their proteomic data with a compiled literature set of 35 proteins implicated in ovarian malignancy, they detected 21 of these targets within healthy postmenopausal ovarian tissue.
Notably, ovarian cancer-associated scores and the expression of several cancer-linked proteins peaked within the 60–69 age cohort. This window aligns closely with the reported median age of approximately 63 years at an ovarian cancer diagnosis. While the authors emphasize that these patterns do not constitute evidence of malignancy or precancerous lesions, the data suggest that the aging postmenopausal microenvironment gradually transitions toward a more permissive, cancer-ready niche.
Additionally, the study identified partial overlap between the ovarian proteomic profiles and established markers of cellular senescence—a state where cells permanently halt division while retaining active secretory signaling. However, concordance was limited to specific stromal and cortical subsets, indicating that ovarian aging involves unique biochemical pathways distinct from standard cellular senescence models.
Contraindications & When to Consult a Doctor
Because these findings represent preliminary, exploratory proteomic research rather than direct clinical diagnostics, patients must not alter hormone management, cancer screening schedules, or preventative surgical decisions based on these molecular signatures.
